Related Experiment Video

Updated: May 28, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

[Pathophysiology and advances in the treatment of Hereditary Angioedema]

Andrea Aída Velasco-Medina1, Guillermina Cortés-Morales, Adriana Barreto-Sosa

  • 1Servicio de Alergia e Inmunología Clínica, Hospital General de México. O.D.

Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
|October 5, 2011
PubMed

Insights

Hereditary angioedema (HAE) is a genetic disorder causing swelling due to a C1 inhibitor enzyme defect. Treatments aim to manage bradykinin, the key mediator, offering new therapeutic avenues.

Area of Science:

  • Genetics
  • Immunology
  • Pharmacology

Background:

  • Hereditary angioedema (HAE) is an autosomal dominant disorder.
  • It results from a deficient or dysfunctional C1 inhibitor enzyme.
  • Bradykinin is the primary mediator of HAE attacks.

Purpose of the Study:

  • To review the pathophysiology of hereditary angioedema.
  • To discuss the different types and clinical manifestations of HAE.
  • To summarize current and emerging treatment strategies for HAE.

Main Methods:

  • Literature review of hereditary angioedema.
  • Analysis of disease mechanisms and mediators.
  • Overview of therapeutic interventions.

Main Results:

  • HAE presents with recurrent angioedema, potentially affecting the periphery, GI tract, or larynx.
  • Three main types of HAE exist, linked to C1 inhibitor levels, function, or Factor XII gene alterations.
  • Various treatments are available, including enzyme replacement and bradykinin pathway inhibitors.

Conclusions:

  • Understanding HAE pathophysiology is crucial for effective management.
  • Targeting bradykinin production or its B2 receptor represents a significant advancement in HAE therapy.
  • Personalized treatment approaches are essential for managing this rare genetic disease.

More Related Videos

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...